

Eugenie S Kleinerman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9230865/publications.pdf>

Version: 2024-02-01

97
papers

5,155
citations

101543

36
h-index

95266

68
g-index

99
all docs

99
docs citations

99
times ranked

5225
citing authors

#	ARTICLE	IF	CITATIONS
1	Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survivalâ€”A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 633-638.	1.6	666
2	Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate. <i>Journal of Clinical Oncology</i> , 2005, 23, 2004-2011.	1.6	649
3	Osteosarcoma Overview. <i>Rheumatology and Therapy</i> , 2017, 4, 25-43.	2.3	317
4	miR-20a Encoded by the miR-17â€”92 Cluster Increases the Metastatic Potential of Osteosarcoma Cells by Regulating Fas Expression. <i>Cancer Research</i> , 2012, 72, 908-916.	0.9	162
5	A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. <i>Clinical and Experimental Metastasis</i> , 1999, 17, 501-506.	3.3	126
6	Antiâ€”PDâ€”1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases. <i>Cancer Medicine</i> , 2018, 7, 2654-2664.	2.8	126
7	A Small Interfering RNA Targeting Vascular Endothelial Growth Factor Inhibits Ewing's Sarcoma Growth in a Xenograft Mouse Model. <i>Clinical Cancer Research</i> , 2005, 11, 2662-2669.	7.0	111
8	Efficacy of Liposomal Muramyl Tripeptide (CGP 19835A) in the Treatment of Relapsed Osteosarcoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1995, 18, 93-99.	1.3	110
9	Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1257, 181-192.	1.6	104
10	Genetically Modified T cells Targeting Interleukin-11 Receptor Î±-Chain Kill Human Osteosarcoma Cells and Induce the Regression of Established Osteosarcoma Lung Metastases. <i>Cancer Research</i> , 2012, 72, 271-281.	0.9	103
11	Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. <i>International Journal of Cancer</i> , 2005, 116, 458-463.	5.1	90
12	Increased Fas Expression Reduces the Metastatic Potential of Human Osteosarcoma Cells. <i>Clinical Cancer Research</i> , 2004, 10, 8114-8119.	7.0	86
13	The Narrow-Spectrum HDAC Inhibitor Entinostat Enhances NKG2D Expression Without NK Cell Toxicity, Leading to Enhanced Recognition of Cancer Cells. <i>Pharmaceutical Research</i> , 2015, 32, 779-792.	3.5	86
14	Exosomal communication by metastatic osteosarcoma cells modulates alveolar macrophages to an M2 tumor-promoting phenotype and inhibits tumoricidal functions. <i>Oncolmmunology</i> , 2020, 9, 1747677.	4.6	75
15	Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEIâ€”p53 complexes. <i>Cancer Gene Therapy</i> , 2001, 8, 619-627.	4.6	70
16	Corruption of the Fas Pathway Delays the Pulmonary Clearance of Murine Osteosarcoma Cells, Enhances Their Metastatic Potential, and Reduces the Effect of Aerosol Gemcitabine. <i>Clinical Cancer Research</i> , 2007, 13, 4503-4510.	7.0	69
17	Murine bone marrowâ€”derived mesenchymal stem cells as vehicles for interleukinâ€”12 gene delivery into Ewing sarcoma tumors. <i>Cancer</i> , 2009, 115, 13-22.	4.1	68
18	Fas-Negative Osteosarcoma Tumor Cells Are Selected during Metastasis to the Lungs: The Role of the Fas Pathway in the Metastatic Process of Osteosarcoma. <i>Molecular Cancer Research</i> , 2007, 5, 991-999.	3.4	63

#	ARTICLE	IF	CITATIONS
19	Early Lymphocyte Recovery as a Prognostic Indicator for High-risk Ewing Sarcoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2007, 29, 48-52.	0.6	62
20	Eradication of osteosarcoma lung metastases following intranasal interleukin-12 gene therapy using a nonviral polyethylenimine vector. <i>Cancer Gene Therapy</i> , 2002, 9, 260-266.	4.6	57
21	Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103 ⁺ conventional dendritic cells. , 2020, 8, e000474.		57
22	Fas expression inversely correlates with metastatic potential in osteosarcoma cells. <i>Oncology Reports</i> , 2002, 9, 823-7.	2.6	57
23	Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 1807-1816.	4.1	54
24	Vasculogenesis Plays a Role in the Growth of Ewing's Sarcoma in Vivo. <i>Clinical Cancer Research</i> , 2002, 8, 3622-7.	7.0	53
25	Aerosol gene therapy with PEI: IL-12 eradicates osteosarcoma lung metastases. <i>Clinical Cancer Research</i> , 2003, 9, 3462-8.	7.0	51
26	Stromal cell-derived factor-1 stimulates vasculogenesis and enhances Ewing's sarcoma tumor growth in the absence of vascular endothelial growth factor. <i>International Journal of Cancer</i> , 2008, 123, 831-837.	5.1	47
27	Bone Marrow Subsets Differentiate into Endothelial Cells and Pericytes Contributing to Ewing's Tumor Vessels. <i>Molecular Cancer Research</i> , 2008, 6, 929-936.	3.4	46
28	CAPER ¹ alternative splicing regulates the expression of vascular endothelial growth factor ₁₆₅ in Ewing sarcoma cells. <i>Cancer</i> , 2012, 118, 2106-2116.	4.1	45
29	Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases. <i>Cancer</i> , 2006, 106, 1382-1388.	4.1	44
30	Fas Expression in Lung Metastasis From Osteosarcoma Patients. <i>Journal of Pediatric Hematology/Oncology</i> , 2005, 27, 611-615.	0.6	42
31	Production of VEGF165 by Ewing's sarcoma cells induces vasculogenesis and the incorporation of CD34 ⁺ stem cells into the expanding tumor vasculature. <i>International Journal of Cancer</i> , 2006, 119, 839-846.	5.1	42
32	Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3802-3810.	7.0	42
33	Association of $\alpha_3\beta_1$ integrin expression with the metastatic potential and migratory and chemotactic ability of human osteosarcoma cells. <i>Clinical and Experimental Metastasis</i> , 2005, 21, 747-753.	3.3	41
34	9- <i>N</i> -Nitrocamptothecin Liposome Aerosol Treatment of Human Cancer Subcutaneous Xenografts and Pulmonary Cancer Metastases in Mice. <i>Annals of the New York Academy of Sciences</i> , 2000, 922, 151-163.	3.8	41
35	The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Metastases. <i>Current Cancer Drug Targets</i> , 2013, 13, 411-422.	1.6	41
36	Suppression of Ewing's Sarcoma Tumor Growth, Tumor Vessel Formation, and Vasculogenesis Following Anti-Vascular Endothelial Growth Factor Receptor-2 Therapy. <i>Clinical Cancer Research</i> , 2007, 13, 4867-4873.	7.0	40

#	ARTICLE	IF	CITATIONS
37	Aerosol Gemcitabine: Preclinical Safety and <i>In Vivo</i> Antitumor Activity in Osteosarcoma-Bearing Dogs. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2010, 23, 197-206.	1.4	39
38	Blocking SDF-1 \pm /CXCR4 Downregulates PDGF-B and Inhibits Bone Marrow-Derived Pericyte Differentiation and Tumor Vascular Expansion in Ewing Tumors. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 483-491.	4.1	37
39	The Role of Fas/FasL in the Metastatic Potential of Osteosarcoma and Targeting this Pathway for the Treatment of Osteosarcoma Lung Metastases. <i>Cancer Treatment and Research</i> , 2009, 152, 497-508.	0.5	37
40	Expression of granulocyte-colony-stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens. <i>Cancer</i> , 2007, 110, 1568-1577.	4.1	36
41	Aerosol Therapy for the Treatment of Osteosarcoma Lung Metastases: Targeting the Fas/FasL Pathway and Rationale for the Use of Gemcitabine. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2010, 23, 189-196.	1.4	36
42	Delta-like ligand 4-Notch signaling regulates bone marrow-derived pericyte/vascular smooth muscle cell formation. <i>Blood</i> , 2011, 117, 719-726.	1.4	36
43	Interleukin-12 Up-Regulates Fas Expression in Human Osteosarcoma and Ewing's Sarcoma Cells by Enhancing Its Promoter Activity. <i>Molecular Cancer Research</i> , 2005, 3, 685-692.	3.4	35
44	Exploratory Analysis of Fas Gene Polymorphisms in Pediatric Osteosarcoma Patients. <i>Journal of Pediatric Hematology/Oncology</i> , 2007, 29, 815-821.	0.6	35
45	Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis. <i>Pediatric Blood and Cancer</i> , 2014, 61, 618-626.	1.5	35
46	Delta-Like Ligand 4 Plays a Critical Role in Pericyte/Vascular Smooth Muscle Cell Formation during Vasculogenesis and Tumor Vessel Expansion in Ewing's Sarcoma. <i>Clinical Cancer Research</i> , 2010, 16, 848-856.	7.0	34
47	E1A gene therapy inhibits angiogenesis in a Ewing's sarcoma animal model. <i>Molecular Cancer Therapeutics</i> , 2003, 2, 1313-9.	4.1	34
48	Effect of entinostat on NK cell-mediated cytotoxicity against osteosarcoma cells and osteosarcoma lung metastasis. <i>Oncolmmunology</i> , 2017, 6, e1333214.	4.6	32
49	Aerobic Exercise During Early Murine Doxorubicin Exposure Mitigates Cardiac Toxicity. <i>Journal of Pediatric Hematology/Oncology</i> , 2018, 40, 208-215.	0.6	32
50	Vascular modulation through exercise improves chemotherapy efficacy in Ewing sarcoma. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27835.	1.5	32
51	SDF-1 \pm Induces PDGF-B Expression and the Differentiation of Bone Marrow Cells into Pericytes. <i>Molecular Cancer Research</i> , 2011, 9, 1462-1470.	3.4	31
52	VEGF165, but not VEGF189, Stimulates Vasculogenesis and Bone Marrow Cell Migration into Ewing's Sarcoma Tumors <i>In vivo</i> . <i>Molecular Cancer Research</i> , 2007, 5, 1125-1132.	3.4	30
53	Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases. <i>Cancer</i> , 2011, 117, 3457-3467.	4.1	30
54	Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1362-1368.	1.5	29

#	ARTICLE	IF	CITATIONS
55	Mechanisms of Kupffer cell cytotoxicity in vitro against the syngeneic murine colon adenocarcinoma line MCA26. <i>Journal of Leukocyte Biology</i> , 1993, 53, 715-721.	3.3	26
56	BMT-11 is active in preclinical models of human osteosarcoma and a candidate targeted drug for clinical translation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 8065-8070.	7.1	26
57	VEGF ₁₆₅ Promotes the Osteolytic Bone Destruction of Ewing's Sarcoma Tumors by Upregulating RANKL. <i>Oncology Research</i> , 2009, 18, 117-125.	1.5	26
58	VEGF165 expression in the tumor microenvironment influences the differentiation of bone marrow-derived pericytes that contribute to the Ewing's sarcoma vasculature. <i>Angiogenesis</i> , 2008, 11, 257-267.	7.2	24
59	Maximum benefit of chemotherapy for osteosarcoma achieved—what are the next steps?. <i>Lancet Oncology</i> , 2016, 17, 1340-1342.	10.7	24
60	Using the Spleen as an <i>In Vivo</i> Systemic Immune Barometer Alongside Osteosarcoma Disease Progression and Immunotherapy with <i>anti</i> -PD-L1. <i>Sarcoma</i> , 2018, 2018, 1-13.	1.3	24
61	ImmTher, a lipophilic disaccharide derivative of muramyl dipeptide, up-regulates specific monocyte cytokine genes and activates monocyte-mediated tumoricidal activity. <i>Cancer Immunology, Immunotherapy</i> , 1999, 48, 312-320.	4.2	23
62	Vasculogenesis Driven by Bone Marrow-Derived Cells Is Essential for Growth of Ewing's Sarcomas. <i>Cancer Research</i> , 2010, 70, 1334-1343.	0.9	23
63	Epigenetic Regulation of Apoptosis and Cell Cycle in Osteosarcoma. <i>Sarcoma</i> , 2011, 2011, 1-5.	1.3	22
64	Participation of the Fas/FasL Signaling Pathway and the Lung Microenvironment in the Development of Osteosarcoma Lung Metastases. <i>Advances in Experimental Medicine and Biology</i> , 2014, 804, 203-217.	1.6	22
65	Interleukin-12 Enhances the Sensitivity of Human Osteosarcoma Cells to 4-Hydroperoxycyclophosphamide by a Mechanism Involving the Fas/Fas-Ligand Pathway. <i>Clinical Cancer Research</i> , 2004, 10, 777-783.	7.0	21
66	EWS-FLI1 regulates the neuronal repressor gene REST, which controls Ewing sarcoma growth and vascular morphology. <i>Cancer</i> , 2014, 120, 579-588.	4.1	21
67	Diet and exercise interventions for pediatric cancer patients during therapy: tipping the scales for better outcomes. <i>Pediatric Research</i> , 2018, 83, 50-56.	2.3	21
68	Tumor Vessel Development and Expansion in Ewing's Sarcoma: A Review of the Vasculogenesis Process and Clinical Trials with Vascular-Targeting Agents. <i>Sarcoma</i> , 2011, 2011, 1-7.	1.3	20
69	Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8+ T Cells and Histone Acetyltransferases. <i>Cancer Immunology Research</i> , 2017, 5, 300-311.	3.4	20
70	Expression of cFLIP in pulmonary metastases in osteosarcoma patients and human xenografts. <i>Pediatric Blood and Cancer</i> , 2013, 60, 575-579.	1.5	19
71	Exercise Inhibits Doxorubicin-Induced Damage to Cardiac Vessels and Activation of Hippo/YAP-Mediated Apoptosis. <i>Cancers</i> , 2021, 13, 2740.	3.7	17
72	Exercise intervention decreases acute and late doxorubicin-induced cardiotoxicity. <i>Cancer Medicine</i> , 2021, 10, 7572-7584.	2.8	17

#	ARTICLE	IF	CITATIONS
73	Exosomes: Dynamic Mediators of Extracellular Communication in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1258, 189-197.	1.6	16
74	Lack of Immunomodulatory Interleukin-27 Enhances Oncogenic Properties of Mutant p53 <i>In Vivo</i> . <i>Clinical Cancer Research</i> , 2016, 22, 3876-3883.	7.0	15
75	Hes4: A potential prognostic biomarker for newly diagnosed patients with high-grade osteosarcoma. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26318.	1.5	15
76	Phosphorylated heat shock protein 27 as a potential biomarker to predict the role of chemotherapy-induced autophagy in osteosarcoma response to therapy. <i>Oncotarget</i> , 2018, 9, 1602-1616.	1.8	15
77	Analysis of HSP27 and the Autophagy Marker LC3B+ Puncta Following Preoperative Chemotherapy Identifies High-Risk Osteosarcoma Patients. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1315-1323.	4.1	13
78	Bone marrow cells participate in tumor vessel formation that supports the growth of Ewing's sarcoma in the lung. <i>Angiogenesis</i> , 2011, 14, 125-133.	7.2	12
79	miR-20a Regulates FAS Expression in Osteosarcoma Cells by Modulating FAS Promoter Activity and Can be Therapeutically Targeted to Inhibit Lung Metastases. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 130-139.	4.1	12
80	Fas Expression in Metastatic Osteosarcoma Cells Is Not Regulated by CpG Island Methylation. <i>Oncology Research</i> , 2009, 18, 31-39.	1.5	9
81	The Fas/FasL Signaling Pathway: Its Role in the Metastatic Process and as a Target for Treating Osteosarcoma Lung Metastases. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1258, 177-187.	1.6	9
82	Knock down of Fas-Associated Protein with Death Domain (FADD) Sensitizes Osteosarcoma to TNF α -induced Cell Death. <i>Journal of Cancer</i> , 2020, 11, 1657-1667.	2.5	8
83	Bempegaldesleukin (BEMPEG ; NKTR 214) efficacy as a single agent and in combination with checkpoint inhibitor therapy in mouse models of osteosarcoma. <i>International Journal of Cancer</i> , 2021, 148, 1928-1937.	5.1	8
84	Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: The university of Texas MD Anderson cancer center experience. <i>Oncoscience</i> , 2014, 1, 522-530.	2.2	7
85	VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells. <i>Journal of Experimental Therapeutics and Oncology</i> , 2008, 7, 89-97.	0.5	7
86	[131I]MIBG exports via MRP transporters and inhibition of the MRP transporters improves accumulation of [131I]MIBG in neuroblastoma. <i>Nuclear Medicine and Biology</i> , 2020, 90-91, 49-54.	0.6	6
87	Short-Term Changes in Skeletal Muscle Mass After Anthracycline Administration in Adolescent and Young Adult Sarcoma Patients. <i>Journal of Adolescent and Young Adult Oncology</i> , 2022, 11, 320-322.	1.3	6
88	Up-regulation of pro-angiogenic molecules and events does not relate with an angiogenic switch in metastatic osteosarcoma cells but to cell survival features. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2021, 26, 447-459.	4.9	5
89	Prognostic Value of Cell-Surface Vimentin-Positive CTCs in Pediatric Sarcomas. <i>Frontiers in Oncology</i> , 2021, 11, 760267.	2.8	5
90	Short-Term Changes in Cardiac Function in Osteosarcoma Patients Receiving Anthracyclines. <i>Journal of Adolescent and Young Adult Oncology</i> , 2019, 8, 385-386.	1.3	4

#	ARTICLE	IF	CITATIONS
91	Neuronal Repressor REST Controls Ewing Sarcoma Growth and Metastasis by Affecting Vascular Pericyte Coverage and Vessel Perfusion. <i>Cancers</i> , 2020, 12, 1405.	3.7	4
92	Aerosol Gemcitabine after Amputation Inhibits Osteosarcoma Lung Metastases but Not Wound Healing. <i>Sarcoma</i> , 2018, 2018, 1-12.	1.3	3
93	Abstract 3008: Effect of exercise on acute and late onset Doxorubicin-induced cardiotoxicity. , 2018, , .		3
94	Metastatic epidural osteosarcoma initially diagnosed as cisplatin neuropathy. <i>Journal of Neuro-Oncology</i> , 1986, 4, 165-167.	2.9	2
95	Abstract 5335: The histone deacetylase inhibitor MS-275 sensitizes osteosarcoma cells and osteosarcoma lung metastases to FasL-induced cell death by the downregulation c-FLIP. , 2011, , .		2
96	Assessment of drug transporters involved in the urinary secretion of [^{99m} Tc]dimercaptosuccinic acid. <i>Nuclear Medicine and Biology</i> , 2021, 94-95, 92-97.	0.6	1
97	Meet the Editorial Board Member. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2021, 21, 87-87.	0.7	0